If I have a patient who wants to have a bottle of wine, and eat a huge steak dinner and have 2,000 calories at 10 oclock at night, and [they] think the medication is going to make them feel well and still lose weight, and not change those sorts of dietary habits, theyre not a good candidate. Side effects, in Mounjaros case, can include nausea, vomiting, stomach pain, diarrhea, and a host of similar symptoms
Phase 3 results are needed No cardiovascular outcomes data available The biased signaling mechanism, while promising, needs long-term validation Exact molecular structure has not been publicly disclosed Phase 3 trials are planned but not yet enrolled Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity , published in Cell Metabolism (Roche/Genentech/Carmot Therapeutics investigators, 2025
What Is "Ozempic Personality," Really
Curr Cardiovasc Risk Rep
Theres not much preliminary data that makes me worried
